Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV Coinfection **ALLY-2 Study**



Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Study Features

ALLY-2: Features


- Design: Phase 3, open-label study of daclatasvir (DCV) plus sofosbuvir (SOF) in treatment-naïve or experienced, chronic HCV GT 1-4 and HIV coinfection
- Setting: Multiple centers in the United States

Entry Criteria

- N = 395 patients enrolled
- Chronic HCV Genotype 1 through 4
- Treatment-naïve or treatment experienced
- Noncirrhotic or compensated cirrhosis (less than 50%)
- Stable ARV with HIV RNA < 50 copies/ml at screening and <200 copies/ml for ≥8 weeks; and CD4 count > 100 cells/mm³
- ARVs allowed: tenofovir, emtricitabine, abacavir, lamivudine, zidovudine, darunavir-ritonavir, atazanavir-ritonavir, lopinavir-ritonavir, efavirenz, nevirapine, rilpivirine, dolutegravir, raltegravir, enfuvirtide, maraviroc
- End-Points: Primary = SVR12



Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Design



Drug Dosing

Daclatasvir: 60 mg once daily; with efavirenz and nevirapine the dose was increased to 90 mg once daily and with ritonavir-boosted protease inhibitors the dose was decreased to 30 mg once daily Sofosbuvir: 400 mg once daily



Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Patient Characteristics

Characteristic	Treatment-Naïve 12-Week Group (n=101)	Treatment-Naïve 8-Week Group (n=50)	Previously Treated 12-Week Group (n=52)
Male, n (%)	92 (91%)	42 (84%)	43 (83%)
Median age, years (range)	52 (24-71)	51 (28-75)	57 (43-66)
Race White Black Asian/other	66 (65%) 30 (30%) 5 (5%)	28 (56%) 19 (38%) 3 (6%)	31 (60%) 20 (38%) 1 (2%)
HCV genotype 1A 1B 2 3 4	71 (70%) 12 (12%) 11 (11%) 6 (6%) 1 (1%)	35 (70%) 6 (12%) 6 (12%) 3 (6%) 0	33 (63%) 11 (21%) 2 (4%) 4 (8%) 2 (4%)
Cirrhosis	9 (9%)	5 (10%)	15 (29%)
Median HCV RNA log ₁₀ (IU/mL)(range)	6.7 (3.3-7.6)	6.4 (4.2-7.5)	6.7 (3.9-7.9)




Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: HIV Characteristics

Characteristic	Treatment-Naïve 12-Week Group (n=101)	Treatment-Naïve 8-Week Group (n=50)	Previously Treated 12-Week Group (n=52)
Median CD4 count (range) — cells/mm ³	520 (122-1147)	575 (157-1430)	636 (262-1470)
HIV-1 RNA <50 copies/ml	94/100 (94%)	45/48 (94%)	47/49 (96%)
Antiretroviral treatment, % Darunavir-ritonavir Atazanavir-ritonavir Lopinavir-ritonavir Efavirenz Nevirapine Rilpivirine Raltegravir Dolutegravir	Total 99% 19% 19% 9% 18% 5% 5% 22% 3%	Total 96% 44% 10% 6% 17% 2% 2% 17% 2%	Total 98% 22% 24% 0 16% 6% 2% 20% 8%
Nucleoside RTI only	0	0	4%




SVR12, Genotype 1



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir




SVR12, Genotype 1 and subtypes



n=11 had missing or inconclusive findings for cirrhosis & not included in denominators




SVR12, Genotype 1, by Liver Status



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir




SVR12, Genotype 2



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir




SVR12, Genotype 3



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir



SVR12, Genotype 4



Abbreviations: DCV = daclatasvir; SOF = sofosbuvir



Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV Coinfection ALLY-2 Trial: Conclusion

Conclusion: "Among previously untreated HIV–HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks."



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.



